Moderate-to-severe (>10% BSA or DLQI >10): systemic or biologic therapy
Emergency presentations: immediate systemic therapy and supportive care
Systemic therapy threshold
BSA >10% or refractory to topicals at adequate trial
Significant quality-of-life impairment (DLQI >10)
Involvement of special sites: face, genitalia, hands/feet, nails affecting function
Associated psoriatic arthritis requiring systemic control
Biologic therapy principles
Screen for TB, hepatitis B/C, and HIV before initiating any biologic
IL-23 inhibitors: highest efficacy with favorable safety; preferred first-line biologic
IL-17 inhibitors: very high efficacy; caution in IBD (may worsen)
TNF inhibitors: avoid in demyelinating disease, CHF NYHA III/IV, or active malignancy
Biosimilars are approved alternatives with equivalent efficacy
Monitoring parameters
Methotrexate: CBC and LFT every 4-8 weeks; cumulative dose hepatotoxicity risk
Cyclosporine: blood pressure and creatinine every 2-4 weeks; limit duration
Acitretin: lipid panel and LFT every 4-8 weeks
Biologics: TB re-screening annually; infection vigilance; skin cancer screening
Avoid systemic corticosteroids in psoriasis
Short-term improvement followed by rebound flare on taper
Risk of GPP induction or erythroderma exacerbation
Class I evidence: systemic corticosteroids are contraindicated for plaque psoriasis
Patient Discharge Instructions
copy discharge instructions
Diagnosis and skin care
You have been diagnosed with a psoriasis flare, a chronic inflammatory skin condition
Psoriasis is not contagious and cannot be spread to others
Flares are expected but manageable with consistent treatment
Apply your topical medication as directed
Apply to affected areas only, avoiding normal skin
Wash hands before and after applying topical medications
Use moisturizers and emollients liberally every day, especially after bathing
Gentle, fragrance-free moisturizers applied within 3 minutes of bathing seal in hydration
Topical steroid taper instructions
Do not stop your topical steroid abruptly once lesions clear
Reduce frequency as directed (every other day for 1 week, then twice weekly) before stopping
Abrupt stopping can cause a rebound flare
Trigger avoidance
Avoid known triggers that worsen psoriasis
Stress: practice relaxation techniques, mindfulness, or exercise
Alcohol: reduces treatment effectiveness and worsens skin inflammation
Smoking: worsens disease severity; cessation resources available
Skin injury: avoid scratching, sunburn, or friction that can cause new lesions
Do not stop any prescription medication without speaking to your doctor first
Stopping corticosteroids abruptly is particularly dangerous
Report any new medications prescribed by other doctors to your dermatologist
Some medications (lithium, beta-blockers, antimalarials) can worsen psoriasis
Lifestyle recommendations
Mediterranean-style diet may help reduce inflammation
Emphasize fruits, vegetables, olive oil, fish, legumes, and whole grains
Limit processed foods, excess sugar, and saturated fats
Weight management: losing weight can improve psoriasis severity and treatment response
Stay well hydrated, especially if your skin is cracked or widespread
Mental health
Psoriasis significantly impacts quality of life; depression and anxiety are common
Speak to your doctor if you are feeling depressed or having thoughts of self-harm
Support groups and mental health resources are available through the National Psoriasis Foundation
Return to emergency department immediately for
Redness spreading to involve most of the body surface
New pustules (pus-filled bumps) appearing on red skin
Fever, chills, or feeling systemically unwell
Signs of skin infection: increasing warmth, swelling, pus, or red streaking
New joint swelling or inability to use hands or feet
Worsening despite 2-4 weeks of prescribed topical treatment
Follow-up instructions
Mild flare: follow up with your family doctor or dermatologist in 2-4 weeks
Bring a list of all medications to each appointment
If you are starting a new systemic medication, follow up in 4 weeks to check response
Biologic therapy follow-up: as per your dermatologist's drug-specific schedule
References
Guidelines and key sources
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN
Psoriasis. Lancet. 2021. PMID 33812489
Comprehensive review of psoriasis pathogenesis, classification, and management
Armstrong AW, Read C
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020
Key review of treatment evidence including biologic therapy hierarchies
Menter A, Gelfand JM, Connor C, et al
Joint AAD-NPF Guidelines of Care for the Management of Psoriasis With Systemic Nonbiologic Therapies. J Am Acad Dermatol. 2020
Authoritative guidelines for methotrexate, cyclosporine, acitretin, and apremilast use
Menter A, Korman NJ, Elmets CA, et al
Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis Section 6. J Am Acad Dermatol. 2011
Evidence-based recommendations for psoriatic arthritis management
Garner KK, Hoy KDS, Carpenter AM
Psoriasis: Recognition and Management Strategies. American Family Physician. 2023. PMID 38215417
Primary care-focused psoriasis management summary
Choon SE, van de Kerkhof P, Gudjonsson JE, et al
International Consensus Definition and Diagnostic Criteria for GPP from the International Psoriasis Council. JAMA Dermatology. 2024
Defines GPP diagnostic criteria and management including spesolimab
National Psoriasis Foundation
GPP: Recognizing and Treating a Dermatologic Emergency. NPF. 2025
Emergency management protocols for erythrodermic and GPP presentations
Mastorino L, Leo F, Frigatti G, et al
Management of Erythrodermic Psoriasis With Systemic Therapies: A Systematic Review. Am J Clin Dermatol. 2025. PMID 40856907
Systematic review of systemic therapy evidence for erythrodermic psoriasis
Landmark trials and scoring resources
Ford AR, Siegel M, Bagel J, et al
Dietary Recommendations for Adults With Psoriasis From the Medical Board of the NPF. JAMA Dermatology. 2018
Mediterranean diet and omega-3 evidence base; NPF strength 2B recommendation
Ko SH, Chi CC, Yeh ML, et al
Lifestyle Changes for Treating Psoriasis. Cochrane Database Syst Rev. 2019
Alcohol avoidance and weight loss as evidence-based adjunctive measures
Boehncke WH, Schon MP
Psoriasis. Lancet. 2015. PMID 26025581
Pathophysiology and comorbidity framework including cardiovascular risk
PASI scoring system
Validated primary endpoint for clinical trials; PASI 75/90/100 as treatment targets
Freely available calculators at psoriasis.org and dermnetnz.org
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.